US Patent Issued to Livactus on Aug. 19 for "Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance" (American, Chinese Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,391,738, issued on Aug. 19, was assigned to Livactus Inc. (Pasadena, Calif.).

"Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance" was invented by Wei-Chiang Shen (San Marino, Calif.), Yuqian Liu (Henan, China) and Hsuan-Yao Wang (Fullerton, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating Type 2 diabetes (T2D) is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes an insulin-transferrin fusion protein or its prodrug, proinsulin-transferrin fusion protein."

The patent was filed on Au...